Skip to main content
  • Our Mission
  • About Us
  • Founders
  • Investors
  • Careers
Copyright © 2023 Kisbee Therapeutics, LLC. All Rights Reserved.

Redefining the treatment of neurodegenerative disease

moving 3d dark liquid material

Our Mission

Changing the paradigm of treating neurodegenerative disease

Our mission is to translate unique genetic and biochemical insights regarding lipid biology into therapies that promote brain health and repair. We believe our novel technology platform and approach will unlock new opportunities to address significant unmet need across a range of acute and chronic conditions, including Traumatic Brain Injury, Stroke, Multiple Sclerosis, and Alzheimer’s Disease.

Our Mission

About Us

Great teams are required to achieve great success

We are a growing team of scientists and entrepreneurs dedicated to advancing our technology in service of patients and their loved ones. With a diverse culture of experience and perspective, we strive to support and challenge one another, fostering an environment of care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. Passionate and driven, we aspire to overcome obstacles with creativity and careful risk-taking, knowing that we are making a difference in the lives of patients.

At Kisbee, we believe that great teams are built on a foundation of kindness, honesty, and balance. We work hard, but recognize that we all have lives outside the lab and office. We celebrate our successes as much as our failures, knowing that both are stepping stones on the journey to changing the way we approach brain health. Together, we will redefine the way we treat neurodegenerative disease.

We Value

  • Inherent trust
  • Unabashed curiosity
  • Fearless pursuit
  • Unconditional respect
  • Thoughtful transparency
About Us

Founders

Meet the experts behind our vision

  • Banjamin Cravatt headshot
    Benjamin Cravatt, PhD
  • Emily Ricq headshot
    Emily Ricq, PhD
  • Jennifer Lippincott-Schwartz headshot
    Jennifer Lippincott-Schwartz, PhD
  • Stuart Schreiber headshot
    Stuart Schreiber, PhD
Founders

Investors

Arch Venture Partners
Newpath Partners
Investors

Join us in our journey to revolutionize the treatment of neurodegenerative disease

Kisbee is an exciting fast-growing company with tremendous career growth opportunity. We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com

Join Us
Careers
Stuart Schreiber headshot

Stuart Schreiber, PhD

Stuart L. Schreiber, Ph.D. is co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and has been a member of the National Academy of Sciences since 1995. His research has been recognized through numerous awards, most recently the Wolf Prize in Chemistry.

Dr. Schreiber’s research integrates chemical biology and human biology to advance the discovery of novel therapeutics. He is known for his use of small molecules to explore biology and medicine, and for his role in the development of the field of chemical biology. His lab discovered mTOR and illuminated the nutrient-response signaling network, histone deacetylase (HDAC) and the role of chromatin marks in gene expression, and with Gerry Crabtree mapped the first membrane to nuclease signaling pathway (calcium–calcineurin–NFAT). His work demonstrated for the first time that drugs can result from: 1) the targeting of protein kinases (sirolimus/mTOR) and protein phosphatases (sandimmune/calcineurin); 2) gene regulation by chromatin-modifying enzymes (vorinostat/HDAC), 3) small-molecule dimerizers that activate cellular processes by enforced proximity (GVH Disease), and 4) targeting of the proteasome (bortezomib/proteasome). These efforts accelerated the development of many additional widely used drugs.

Dr. Schreiber extended chemical biology principles to medicine by founding several biotech companies, including Vertex Pharmaceuticals (fosamprenavir/Lexiva; telaprevir/Incivek; ivacaftor/Kalydeco), ARIAD Pharmaceuticals (ponatinib/Iclusig; brigatinib/Alunbrig; ridaforolimus; AP1903), Infinity Pharmaceuticals (reta¬spimycin; duvelisib), Forma Therapeutics, H3 Biomedicine and Jnana Therapeutics.

Copyright © 2023 Kisbee Therapeutics, Inc. All Rights Reserved.
Redefining the treatment of neurodegenerative disease
  • Our Mission
  • About Us
  • Founders
  • Investors
  • Careers